Tumor Mutational Burden as a Pan-cancer Biomarker for Immunotherapy: The Limits and Potential for Convergence.

Détails

Demande d'une copieDemande d'une copie
ID Serval
serval:BIB_BE5AFDD22C20
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Lettre (letter): communication adressée à l'éditeur.
Collection
Publications
Institution
UNIL/CHUV
Titre
Tumor Mutational Burden as a Pan-cancer Biomarker for Immunotherapy: The Limits and Potential for Convergence.
Périodique
Cancer cell
Auteur⸱e⸱s
Passaro A., Stenzinger A., Peters S.
ISSN
1878-3686 (Electronic)
ISSN-L
1535-6108
Statut éditorial
Publié
Date de publication
09/11/2020
Peer-reviewed
Oui
Volume
38
Numéro
5
Pages
624-625
Langue
anglais
Notes
Publication types: Journal Article
Publication Status: ppublish
Résumé
A recent study in The Lancet Oncology reports that high tumor mutational burden (TMB) is associated with response to anti-PD-1 pembrolizumab, leading to the second FDA approval of a tissue-agnostic predictive biomarker for immunotherapy in solid tumors. This is a step forward in realizing the full potential of cancer immunotherapy.
OAI-PMH
oai:serval.unil.ch:BIB_BE5AFDD22C20
DOI
10.1016/j.ccell.2020.10.019
Pubmed
33171127
Web of science
000589896200011
Création de la notice
16/11/2020 14:33
Dernière modification de la notice
16/12/2020 6:24
Données d'usage